AstraZeneca has initiated a Phase III trial to assess the efficacy of its experimental MEK inhibitor selumetinib, in combination with docetaxel, as a second-line treatment for locally advanced or metastatic KRAS mutation-positive nonsmall-cell lung cancer. The firm said the study, which will involve 220 centers and 634 patients, will be the biggest prospective trial involving this patient population.

Full Story:
PharmaTimes (U.K.)

Related Summaries